All News
Case series of 5 patients with binutuzumab (CD20) in AAV
Short story short; it worked. Of course it worked. Obviously it worked. Everyone knew it would work.
Why aren't we doing more TRIALS with new/better B cell inhibitors in AAV?
#ACR25 @RheumNow Abstr#1601 https://t.co/H6Zz3Tf3xo
Mike Putman EBRheum ( View Tweet)
Don’t forget
👇
#lcSSc Pts can get and progress #ILD
1/3 of #limited #cutaneous #systemic #sclerosis #scleroderma GET ILD
From #EUSTAR
>14% progress
Esp +Scl70
Remember to screen #CREST Pts
& allow these Pts into lung disease trials
#ACR25 @RheumNow @ACRheum abst#0879 https://t.co/X15tUgClzN
Links:
Janet Pope Janetbirdope ( View Tweet)
Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores
Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N
Bella Mehta bella_mehta ( View Tweet)
Safety & benefit of #Deucravacitinib in #SLE #LTE #PAISLEY #RCT
👇
over 4 yrs
Stable response sustained over 4 yrs
No new Safety signals
Await Ph3 RCT results - fully enrolled
#SoTyktu
Abst#LB10 #ACR25 @RheumNow @ACRheum https://t.co/ZpmzOYVnq9
Janet Pope Janetbirdope ( View Tweet)
Avouac et al. Lipid changes after JAKi initiation. 85 patients. Increases at 6 months. Largely appeared driven by HDL increase, and correlated CRP decrease. Appeared transient with return to baseline with time. @RheumNow #ACR25 Abstr#1333 https://t.co/CQ6u3ck1Ch
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Ultra-low dose (ULD) RTX in AAV maintenance
200mg q6 mo vs. 500mg q6 mo interim analysis
No major difference in infection risk or hypogammaglobulinemia thus far but both doses appeared similarly efficacious
#ACR25 @rheumnow Abst 1609 https://t.co/ZGYNVGY3dr
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Icotrokinra, the new kid on the bloc!
Targeted oral peptide IL-23R-inhibitor
Effective in Ph2 and Ph3 in PSO Adults
Data in Adolescents (12-18yo) with PSO
ICO 200mg QD 44pts vs. PBO 22pts 16wks
All pts received ICO wk16-wk24
Clear/Almost clear skin IGA 0/1 84% vs. 24%
PASI 90 https://t.co/77YvXtdLi1
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences.
@RheumNow #ACR25 A#1042
Jiha Lee JihaRheum ( View Tweet)
Many GLP-1 drugs in the pipeline for management in #OA
#ACR25 @rheumnow https://t.co/y3UCp0CcUb
Bella Mehta bella_mehta ( View Tweet)
#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Open-label MTX vs. Toci in GCA in METOGiA
Wk 78:
37% w/o relapse in MTX arm
46% w/o relapse in Toci arm
MTX was NOT non-inferior to Toci
Toci superior in 2ndary endpoints
Cumulative doses GC not significantly different
#ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Open label noninferiority RCT "METOGiA" in GCA
TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78
Everyone also got pred; are we sure MTX works at all?
@RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7
Links:
Mike Putman EBRheum ( View Tweet)
#ACR25 Abstr#1526 Finally it’s here! Consensus-based guidance on GC #steroid tapering in patients with #SLE. Included considerations before tapering, tapering schedules and monitoring during tapering. Looking forward to the uptake and hearing patients’ views @RheumNow #ACRBest https://t.co/FFl2TFhtTa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls
Without much surprise GLP-1 treated pts had lower risk of MACE and death
Observational, retrospective study.
Now awaiting the prospective evidence.
RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK
Aurelie Najm AurelieRheumo ( View Tweet)
Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube
@alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology:
- bias at scale
- erosion of skills
- data regulatory issues
(for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better)
@RheumNow https://t.co/FyNes40Z7q
David Liew drdavidliew ( View Tweet)
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed @RheumNow #ACR2025 https://t.co/qazQNk4ovR
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
